Gengos joins the Cambridge-based team as the company focuses on advancing its pipeline of late-stage cancer treatments. He takes over financial oversight from Mallory Morales, the company’s senior vice president of finance, who has been serving as the firm’s principal financial and accounting officer.
Andrew Gengos Joins Immuneering as Chief Financial Officer
Andrew Gengos has stepped into the role of chief financial officer at Immuneering, a clinical-stage oncology firm. His appointment follows his tenure at Terns Pharmaceuticals, where he directed finance and corporate development until the company’s recent acquisition by Merck & Co. last month.
Comments (0)
No comments yet. Be the first!